Developments in hepatitis C therapy during 2000 - 2002

Expert Opinion on Emerging Drugs

Volumn 8, Issue 1, 2003, Pages 9-25

  Poordad, F Fred ^a   Tran, Tram ^a   Martin, Paul ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

Antisense oligonucleotide; Helicase inhibitors; Hepatitis C virus (HCV); Immunomodulators; Nucleoside analogue; Pegylated interferon; Protease inhibitors; Ribozymes

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN ALPHA INTERFERON; AMANTADINE; ANTISENSE OLIGODEOXYNUCLEOTIDE; BETA1A INTERFERON; CYTOKINE; FAS ANTIGEN; GAMMA1B INTERFERON; HEPATITIS C VACCINE; HEPTAZYME; HISTAMINE H2 RECEPTOR; IMMUNOMODULATING AGENT; INTERFERON; ISIS 14803; LEVOVIRIN; MONOCLONAL ANTIBODY; NUCLEOSIDE DERIVATIVE; OMEGA INTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAMIDINE; RIBAVIRIN; RIBONUCLEASE H; RIBOZYME; RNA POLYMERASE; SERINE PROTEINASE; TAU INTERFERON; THYMOSIN ALPHA1; UNCLASSIFIED DRUG; UNINDEXED DRUG; VIRUS RNA;

ABDOMINAL PAIN; ANTIVIRAL ACTIVITY; CLINICAL TRIAL; DEPRESSION; DRUG EFFICACY; DRUG RESEARCH; ENZYME INHIBITION; FLU LIKE SYNDROME; HEADACHE; HEMATOLOGIC DISEASE; HEMOLYTIC ANEMIA; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IMMUNOTHERAPY; LEUKOPENIA; LIVER DYSFUNCTION; LIVER FIBROSIS; LIVER TRANSPLANTATION; NOSE CONGESTION; REVIEW; SIDE EFFECT; TERATOGENICITY; THROMBOCYTOPENIA; VACCINATION;

ANIMALS; CLINICAL TRIALS; GENE THERAPY; HEPACIVIRUS; HEPATITIS C; HUMANS; TECHNOLOGY, PHARMACEUTICAL; VIRAL HEPATITIS VACCINES;

EID: 0038657769     PISSN: 14728214     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728214.8.1.9     Document Type: Review

References (39)

1. ALTER MJ, KRUSZON-MORAN D, NAINAN OV et al.: The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N. Engl. J. Med. (1999) 341:556-562. A very good description of the epidemiology of HCV.
2. DI BISCELGLIE AM: Natural history of hepatitis C: its impact on clinical management. Hepatology (2000) 31:1014-1018.
3. MCHUTCHINSON JG, GORDON SC, EUGENE E et al.: Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N. Engl. J. Med (1998) 335:1485-1492.
4. 2a.
5. 2b.
6. ZEUZEM S, FEINMAN SV, RASENACK J et al.: Evaluation of the safety and efficacy of once weekly PEG/interferon alfa-2a (Pegasys) for chronic hepatitis C. A multinational, randomized study J. Hepatol. (2000) 32(Suppl. 2):29.
7. GLUE P, FANG JW, ROUZIER-PANI R et al.: Pegylated interferon alpha 2b: pharmacokinetics, pharmacodynamics, safety and preliminary efficacy data. Hepatitis C Intervention Therapy Group. Clin Pharmacol Ther. (2000) 68(5):556-567. A good description of the kinetics of PEG-IFN.
8. HADZIYANNIS SJ, CHEINQUER H, MORGAN T et al.: Peg interferon alfa-2a (40Kd) (Pegasys) in combination with ribavirin: efficacy and safety results from a Phase III, randomized double-blind, multicentre study examining effect of duration of treatment and ribavirin dose. J. Hepatol. (2002) 36(Suppl. 1):1.
9. SAUNIER B, TRIYATNI M, ULIANICH L, MARUVADA P, YEN P, KOHN LD: Role of the asialoglycoprotein receptor in binding and entry of hepatitis C virus structural proteins in cultured human hepatocytes. J. Virol. (2003) 77(1):546-559.
10. BILLICH A: Thymosin alpha1, SciClone Pharmaceuticals. Curr. Opin. Investig. Drugs (2002) 3(5):698-707.
11. ANDERSON KS: The molecular basis of inhibition and toxicity of modified cytosine analogues targeting HIV-1 reverse transcriptase. Antivirus Chem. Chemother. (2001) 12(Suppl. Y) 1:13-17.
12. GRACE JD, CAMERON CE: Quasispecies, error catastrophe, and the antiviral activity of ribavirin. Virology (2002) 298(2):175-180.
13. CORRITORI S, LAU JY, LIN C: Safety studies of levovirin, a second generation ribavirin candidate, showed excellent safety profile. Hepatology (2001) 34(4):219A.
14. VON WEIZSACKER F, WEILAND S, KOCK J et al.: Gene therapy for chronic viral hepatitis: ribozymes, antisense oligonucleotides and dominant negative mutants. Hepatology (1996) 26:251-255.
15. BARTENSCHLAGER R: Molecular targets in inhibition of hepatitis C virus replication. Antiviral Chem. Chemother. (1997) 8:281-302. A good review of targets for drug development.
16. LEHMANN TJ, SERWE M, CASELMANN WH, ENGELS JW: Design and properties of hepatitis C virus antisense oligonucleotides for liver specific drug targeting. Nucleosides Nucleotides Nucleic Acids (2001) 20(4-7):1343-1346.
17. ZHANG H, HANECAK R, BROWN-DRIVER V et al.: Antisense oligonucleotide inhibition of hepatitis C virus (HCV) gene expression in livers of mice infected with an HCV-vaccinia virus recombinant. Antimicrob. Agents Chemother. (1999) 43(2):347-353.
18. WITHERELL GW: ISIS 14803 (Isis Pharmaceuticals). Curr. Opin. Investig. Drugs (2001) 11:1523-1529.
19. KWOH TJ, YU RZ, GEARY RS et al.: Clinical pharmacokinetics of ISIS 14803, an antisense inhibitor of HCV, in patients with chronic HCV and comparison to non-clinical pharmacokinetics/toxicology in monkeys. Hepatology (2001) 34(4):331A.
20. OSTERWALDER T, YOON KS, WHITE BH, KESHISHIAN H: A conditional tissue-specific transgene expression system using inducible GAL4. Proc. Natl. Acad. Sci. USA (2001) 98(22):12596-12601.
21. ROMAN G, ENDO K, ZONG L, DAVIS RL: P[Switch], a system for spatial and temporal control of gene expression in Drosophila melanogaster. Proc. Natl. Acad. Sci. USA (2001) 98(22):12602-12607.
22. KRUEGER M, BEGER C, WELCH PJ, BARBER JR, MANNS MP, WONGSTAAL F: Involvement of proteasome alpha-subunit PSMA7 in hepatitis C virus internal ribosome entry site-mediated translation. Mol. Cell. Biol. (2001) 21(24):8357-8364.
23. DAVIES K: Ribozyme technology. Cech wins first patent. Nature (1991) 349(6309):449.
24. WELSH PJ, YEI S, BARBER JR: Ribozyme gene therapy for hepatitis C virus infection. Clin. Diagn. Virol. (1998) 10:163-171.
25. PLEY HW, FLAHERTY KM, MCKAY DB: Three-dimensional structure of a hammerhead ribozyme. Nature (1994) 372:68-74.
26. MACEJAK DG, JENSEN KL, JAMISON SF et al.: Inhibition of hepatitis C virus (HCV-) RNA dependent translation and replication of a chimeric HCV poliovirus using synthetic stabilized ribozymes. Hepatology (2000) 31(3):769-776.
27. TESSMANN K, ERHARDT A, HAUSSINGER D, HEINTGES T: Cloning and molecular characterization of human high affinity antibody fragments against Hepatitis C virus NS3 helicase. J. Virol. Methods (2002) 103(1):75-88.
28. LOCATELLI GA, GOSSELIN G, SPADARI S, MAGA G: Hepatitis C virus NS3 NTPase/helicase: different stereoselectivity in nucleoside triphosphate utilization suggests that NTPase and helicase activities are coupled by a nucleotide-dependent rate limiting step. J. Mol. Biol. (2001) 313(4):683-694.
29. HEINTGES T, ENCKE J, ZU PUTLITZ J, WANDS JR: Inhibition of hepatitis C virus NS3 function by antisense oligodeoxynucleotides and protease inhibitor. J. Med. Virol. (2001) 65(4):671-680. A good description of NS3 function of HCV.
30. MCHUTCHISON JG, CHEUNG R, SHIFFMAN M et al.: A 4 week trial of VX 497 (an IMPDH inhibitor) combined with interferon in previously untreated patients with chronic hepatitis C. Hepatology (2001) 34(2):329A.
31. HELBLING B, STAMENIC I, VIANI F et al.: Interferon and amantiadine in naive chronic hepatitis C: a double-blind, randomized, placebo-controlled trial. Hepatology (2002) 35(2):447-454.
32. MERCER DF, SCHILLER DE, ELLIOTT JF et al.: Hepatitis C virus replication in mice with chimeric human livers. Nat. Med. (2001) 7(8):927-933. An important paper of HCV replication in a mouse model.
33. LECHMANN M, MURATA K, SATOI J et al.: Hepatitis C virus-like particles induce virus-specific humoral and cellular immune responses in mice. Hepatology (2001) 34(2):417-423.
34. BRINSTER C, MUGUET S, LONE YC et al.: Different hepatitis C virus nonstructural protein 3 (Ns3)-DNA-expressing vaccines induce in HLA-A2.1 transgenic mice stable cytotoxic T lymphocytes that target one major epitope. Hepatology (2001) 34(6):1206-1217.
35. HUNZIKER IP, ZURBRIGGEN R, GLUECK R et al.: Perspectives: towards a peptide-based vaccine against hepatitis C virus. Mol. Immunol. (2001) 38(6):475-484.
36. HEVEY M, NEGLEY D, VAN DER ZANDEN L et al.: Marburg virus vaccines: comparing classical and new approaches. Vaccine (2001) 12(3-4):586-593.
37. DOCKRELL DH, KINGHORN GR: Imiquimod and resiquimod as novel immunomodulators. Antimicrob. Chemother. (2001) 48(6):751-755.
38. O'BRIEN CB, MOONKA DK, HENZEL BS et al.: A pilot trial of recombinant interleukin-12 in patients with chronic hepatitis C who previously failed treatment with interferon alpha. Am. J. Gastroenterol. (2001) 96(8):2473.
39. TAO SH, BOLGER PM, REGUL R: Hazard assessment of germanium supplements. Reg. Toxicol. & Pharmacol. (1997) 25(3):211-219.